Royalty Pharma (RPRX) Cash from Investing Activities (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) Cash from Investing Activities (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Royalty Pharma | 25.71 Bn | 25.10 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.63% |
| Dec 31, 2025 | 11.53% |
| Sep 30, 2025 | -207.17% |
| Jun 30, 2025 | -161.91% |
| Mar 31, 2025 | 199.67% |
| Dec 31, 2024 | 57.61% |
| Sep 30, 2024 | -33.53% |
| Jun 30, 2024 | -930.79% |
| Mar 31, 2024 | 91.34% |
| Dec 31, 2023 | -121.94% |
| Sep 30, 2023 | -610.45% |
| Jun 30, 2023 | 88.64% |
| Mar 31, 2023 | -234.67% |
| Dec 31, 2022 | 129.10% |
| Sep 30, 2022 | -4,622.48% |
| Jun 30, 2022 | -370.29% |
| Mar 31, 2022 | 102.02% |
| Dec 31, 2021 | 34.76% |
| Sep 30, 2021 | -770.15% |
| Jun 30, 2021 | 121.05% |